Claude-Henry Volmar

Dr. Claude-Henry Volmar

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CPChiara Pastori
Chiara Pastori
PKPhilipp Kapranov
Philipp Kapranov
CPClara Penas
Clara Penas
VPVeronica Peschansky
Veronica Peschansky
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
Claes WahlestedtClaes Wahlestedt
Claes Wahlestedt
Significance: Glioblastoma Multiforme (GBM) is the most common and deadliest primary brain tumor in adults. As the median survival is approximately 14 mo there is an urgent need for novel therapies. Epigenetic modulators such as bromodomain and extraterminal (BET) proteins are important therapeutic targets in GBM. Bromodomain inhibitors (including I-BET151) suppress proliferation by repressing oncogenes and inducing tumor suppressor genes through unidentified pathways. Here we demonstrate that HOTAIR (HOX transcript antisense RNA) is overexpressed in GBM, where it is crucial to sustain tumor cell proliferation, and that inhibition of HOTAIR by I-BET151 is necessary to induce cell cycle arrest in GBM cells. Our study outlines the mechanism of action underlying the antiproliferative activity of I-BET151, showing for the first time, to our knowledge, that the oncogenic long noncoding RNA HOTAIR is a major target.

5 November 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KJKarolina J. Janczura
Karolina J. Janczura
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
GSGregory C. Sartor
Gregory C. Sartor
SRSunil J. Rao
Sunil J. Rao
NRNatalie R. Ricciardi
Natalie R. Ricciardi
Claes WahlestedtClaes Wahlestedt
Claes Wahlestedt
Alzheimer’s disease (AD) is the leading cause of age-related dementia. Neuropathological hallmarks of AD include brain deposition of β-amyloid (Aβ) plaques and accumulation of both hyperphosphorylated and acetylated tau. RGFP-966, a brain-penetrant and selective HDAC3 inhibitor, or HDAC3 silencing, increases BDNF expression, increases histone H3 and H4 acetylation, decreases tau phosphorylation and tau acetylation at disease-associated sites, reduces β-secretase cleavage of the amyloid precursor protein (APP), and decreases Aβ 1–42 accumulation in HEK-293 cells overexpressing APP with the double Swedish mutation (HEK/APP sw ). In the triple transgenic AD mouse model (3xTg-AD), repeated administration of 3 and 10 mg/kg of RGFP-966 reverses pathological tau phosphorylation at Thr 181 , Ser 202 , and Ser 396 , increases levels of the Aβ degrading enzyme Neprilysin in plasma, decreases Aβ 1–42 protein levels in the brain and periphery, and improves spatial learning and memory. Finally, we show that RGFP-966 decreases Aβ 1–42 accumulation and both tau acetylation and phosphorylation at disease residues in neurons derived from induced pluripotent stem cells obtained from APOEε4-carrying AD patients. These data indicate that HDAC3 plays an important regulatory role in the expression and regulation of proteins associated with AD pathophysiology, supporting the notion that HDAC3 may be a disease-modifying therapeutic target.

1 January 2015 in Neuroepigenetics
Verified
Journal Article
Open access
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
CWClaes Wahlestedt
Claes Wahlestedt
Modulation of gene expression is a constant and necessary event for mammalian brain function. An important way of regulating gene expression is through the remodeling of chromatin, the complex of DNA, and histone proteins around which DNA wraps. The “histone code hypothesis” places histone post-translational modifications as a significant part of chromatin remodeling to regulate transcriptional activity. Acetylation of histones by histone acetyl transferases and deacetylation by histone deacetylases (HDACs) at lysine residues are the most studied histone post-translational modifications in cognition and neuropsychiatric diseases. Here, we review the literature regarding the role of HDACs in brain function. Among the roles of HDACs in the brain, studies show that they participate in glial lineage development, learning and memory, neuropsychiatric diseases, and even rare neurologic diseases. Most HDACs can be targeted with small molecules. However, additional brain-penetrant specific inhibitors with high central nervous system exposure are needed to determine the cause-and-effect relationship between individual HDACs and brain-associated diseases

3 February 2014 in Epigenetics
Verified
Journal Article
Open access
CPChiara Pastori
Chiara Pastori
MDMark Daniel
Mark Daniel
CPClara Penas
Clara Penas
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
AJAndrea L Johnstone
Andrea L Johnstone
NANagi G Ayad
Nagi G Ayad
Epigenetic proteins have recently emerged as novel anticancer targets. Among these, bromodomain and extra terminal domain (BET) proteins recognize lysine-acetylated histones, thereby regulating gene expression. Newly described small molecules that inhibit BET proteins BRD2, BRD3, and BRD4 reduce proliferation of NUT (nuclear protein in testis)-midline carcinoma, multiple myeloma, and leukemia cells in vitro and in vivo. These findings prompted us to determine whether BET proteins may be therapeutic targets in the most common primary adult brain tumor, glioblastoma (GBM). We performed NanoString analysis of GBM tumor samples and controls to identify novel therapeutic targets. Several cell proliferation assays of GBM cell lines and stem cells were used to analyze the efficacy of the drug I-BET151 relative to temozolomide (TMZ) or cell cycle inhibitors. Lastly, we performed xenograft experiments to determine the efficacy of I-BET151 in vivo. We demonstrate that BRD2 and BRD4 RNA are significantly overexpressed in GBM, suggesting that BET protein inhibition may be an effective means of reducing GBM cell proliferation. Disruption of BRD4 expression in glioblastoma cells reduced cell cycle progression. Similarly, treatment with the BET protein inhibitor I-BET151 reduced GBM cell proliferation in vitro and in vivo. I-BET151 treatment enriched cells at the G1/S cell cycle transition. Importantly, I-BET151 is as potent at inhibiting GBM cell proliferation as TMZ, the current chemotherapy treatment administered to GBM patients. Since I-BET151 inhibits GBM cell proliferation by arresting cell cycle progression, we propose that BET protein inhibition may be a viable therapeutic option for GBM patients suffering from TMZ resistant tumors.

30 May 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
OKOlga Khorkova
Olga Khorkova
JSJack Stahl
Jack Stahl
AJAswathy Joji
Aswathy Joji
Claude-Henry VolmarClaude-Henry Volmar
Claude-Henry Volmar
Claes WahlestedtClaes Wahlestedt
Claes Wahlestedt

14 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
VSVasileios Stathias
Vasileios Stathias
AJAnna M. Jermakowicz
Anna M. Jermakowicz
MMMarie E. Maloof
Marie E. Maloof
MFMichele Forlin
Michele Forlin
WWWinston Walters
Winston Walters
NANagi G. Ayad
Nagi G. Ayad
Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed SynergySeq to identify drug combinations for the treatment of GBM by integrating information from The Cancer Genome Atlas (TCGA) and the Library of Integrated Network-Based Cellular Signatures (LINCS). We identify differentially expressed genes in GBM samples and devise a consensus gene expression signature for each compound using LINCS L1000 transcriptional profiling data. The SynergySeq platform computes disease discordance and drug concordance to identify combinations of FDA-approved drugs that induce a synergistic response in GBM. Collectively, our studies demonstrate that combining disease-specific gene expression signatures with LINCS small molecule perturbagen-response signatures can identify preclinical combinations for GBM, which can potentially be tested in humans.